Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice

BACKGROUND: Palivizumab has been shown to reduce the risk of hospitalization caused by respiratory syncytial virus in children with congenital heart disease (CHD). Guidelines published in 2003 by the Canadian Paediatric Society (CPS) stated that children younger than 24 months with hemodynamically s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Bellavance, Marc, Rohlicek, Charles V, Bigras, Jean-Luc, Côté, Jean-Marc, Paquet, Marc, Lebel, Marc H, Mackie, Andrew S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Pulsus Group Inc 2006
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2435318/
https://ncbi.nlm.nih.gov/pubmed/19030237
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg